Lynn Malec, MD: Efanesoctocog alfa Reduces Bleeds, Treatment Burden for Hemophilia

Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community.

Related Keywords

,Lynn Malec ,College Of Wisconsin ,Drug Administration ,Versiti Blood Research Institute ,International Society On Thrombosis ,International Society ,Comprehensive Center ,Bleeding Disorders ,Medical College ,Breakthrough Therapy ,